Exelon Patch, which delivers rivastigmine for Alzheimer's-type dementia, needs a daily check for correct use, side effects, and skin reactions. Caregivers should also flag treatment gaps longer than three days and medicines or conditions that require prescriber review. The patch may help treat mild, moderate, or severe Alzheimer's-type dementia, but it does not cure the disease or stop patients from worsening over time, according to the FDA-approved Novartis prescribing information.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Check the patch every day
- Apply and rotate it correctly
- Monitor appetite, digestion, and hydration
- Know when a skin reaction needs attention
- Review dose changes, interruptions, and other medicines
Check the patch every day
Replace the patch every 24 hours. before applying the new one, remove the old patch and confirm that no other patch remains on the body.
Use this daily checklist: This one-patch check is critical. The FDA prescribing information warns that wearing multiple patches has caused serious reactions, hospitalization, and, rarely, death.
- Remove yesterday's patch.
- Confirm that the patient is wearing no other patch.
- Apply one new patch.
- Record the date, time, dose, and application site.
- Check whether the previous site is irritated.
Apply and rotate it correctly
Apply the patch only to clean, dry, hairless, intact skin. Do not place it on skin that is cut, irritated, or otherwise damaged. Choose a different application site each day.
Do not reuse the exact same spot for at least 14 days. A written site-rotation log can prevent accidental reuse when several caregivers share responsibility. Record the location precisely rather than writing only "back" or "side." Numbering eligible spots on a simple body outline can make the rotation easier to follow.
Monitor appetite, digestion, and hydration
Watch for nausea, vomiting, diarrhea, reduced appetite, weight loss, and dehydration. These effects are dose-related and can become serious, especially when vomiting or diarrhea limits fluid intake.
Keep a brief daily symptom record: These symptoms may require medical review or an interruption in treatment. The FDA-approved prescribing information identifies gastrointestinal effects, weight loss, and dehydration as important risks to monitor.
- Note episodes of nausea, vomiting, or diarrhea.
- Record reduced appetite or skipped meals.
- Track weight consistently.
- Look for signs that fluid intake has fallen.
- Contact the prescriber when symptoms are persistent, worsening, or concerning.
Know when a skin reaction needs attention
Mild irritation limited to the patch area differs from a possible allergic contact reaction. Remove the patch and contact the prescriber if the reaction spreads beyond its outline, becomes intensely red, swollen, raised, or blistered. The patient should also stop using Exelon Patch and contact the prescriber if the reaction does not clearly improve within 48 hours after removal.
These features may indicate allergic contact dermatitis rather than ordinary site irritation. Document when the patch was removed and how the area changed. A photo may help the prescriber assess whether the redness is spreading or improving.
Review dose changes, interruptions, and other medicines
Treatment normally begins with one 4.6-mg/24-hour patch. Dose increases require at least four weeks at the previous tolerated dose, and 9.5 mg/24 hours is the minimum effective dose for mild-to-moderate Alzheimer's disease. If treatment stops for more than three days, contact the prescriber before restarting.
The FDA labeling calls for restarting titration at 4.6 mg/24 hours to reduce the risk of severe vomiting. Make sure the prescriber reviews beta-blockers, metoclopramide, and medicines with cholinergic or anticholinergic effects. The review should also cover ulcers, NSAID use, and cardiac-conduction problems because rivastigmine may interact with these medicines or increase related risks.
